Why TP53 status does not associate with clinical endpoints in ovarian cancer: Facts and hypotheses

Gynecologic Oncology

Volumn 100, Issue 1, 2006, Pages 5-7

  Kupryjańczyk, Jolanta ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATINUM DERIVATIVE; PROTEIN P53; TRASTUZUMAB;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE ARREST; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; EDITORIAL; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; LAPAROTOMY; MUTATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29144460107     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.08.003     Document Type: Editorial

References (23)

1. A.P. Crijns, H.M. Boezen, and J.P. Schouten Prognostic factors in ovarian cancer: current evidence and future prospects Eur. J. Cancer 39 Suppl 6 2003 127 145
2. M. Baekelandt, G.B. Kristensen, J.M. Nesland, C.G. Trope, and R. Holm Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer J. Clin. Oncol. 17 1999 2061
3. L.C. Hartmann, K.C. Podratz, and G.L. Keeney Prognostic significance of p53 immunostaining in epithelial ovarian cancer J. Clin. Oncol. 12 1994 64 69
4. G. Ferrandina, A. Fagotti, and M.G. Salerno p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer Br. J. Cancer 81 1999 733 740
5. G.H. Eltabbakh, J.L. Belinson, and A.W. Kennedy p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer Cancer 80 1997 892 898
6. J. Kupryjańczyk, T. Szymanska, and R. Madry Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen Br. J. Cancer 88 2003 848 854
7. R. Brown Cellular responses to DNA damage and cisplatin resistance F. Sharp T. Blackett R. Leake J. Berek Ovarian cancer 4 1996 Chapmann and Hall Medical Chapter 22
8. A. Fajac, J. Da Silva, and J.C. Ahomadegbe Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line Int. J. Cancer 68 1996 67 74
9. W.M. Gallagher, M. Cairney, B. Schott, I.B. Roninson, and R. Brown Identification of p53 genetic suppressor elements which confer resistance to cisplatin Oncogene 14 1997 185 193
10. G. Coukos, and S.C. Rubin Chemotherapy resistance in ovarian cancer: new molecular perspectives Obstet. Gynecol. 91 5 pt 1 1998 783 792
11. E. Dogan, U. Saygili, and B. Tuna p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis Gynecol. Oncol. 97 2005 46 52
12. J. Kupryjańczyk TP53 status determines prognostic and predictive factors in ovarian carcinomas E. Bardos Trends in Ovarian Cancer Research 2004 Nova Science New York 93 111
13. J. Kupryjańczyk, R. Madry, and J. Plisiecka-Halasa TP53 status determines clinical significance of ERBB2 expression in ovarian cancer Br. J. Cancer 91 2004 1916 1923
14. M.D. Pegram, R.S. Finn, K. Arzoo, M. Beryt, R.J. Pietras, and D.J. Slamon The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 1997 537 547
15. C.O. Bellamy p53 and apoptosis Br. Med. Bull. 53 1997 522 538
16. D.S. Hawkins, G.W. Demers, and D.A. Galloway Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents Cancer Res. 56 1996 892 898
17. R.V. Sionov, and Y. Haupt The cellular response to p53: the decision between life and death Oncogene 18 1999 6145 6657
18. L. Havrilesky, M. Darcy, and H. Hamdan Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 21 2003 3814 3825
19. S.C. Righetti, G. Della Torre, and S. Pilotti A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Cancer Res. 56 1996 689 693
20. F. Buttitta, A. Marchetti, and A. Gadducci p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study Br. J. Cancer 75 1997 230 235
21. H. Lincet, L. Poulain, and J.S. Remy The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells Cancer Lett. 161 2000 17 26
22. G.C. Huang, S. Hobbs, M. Walton, and R.J. Epstein Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells Br. J. Cancer 86 2002 1104 1109
23. P. Casalini, L. Botta, and S. Menard Role of p53 in HER2-induced proliferation or apoptosis J. Biol. Chem. 276 2001 12449 12453